Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 8;12(4):115-122.
doi: 10.4103/jrpp.jrpp_40_24. eCollection 2023 Oct-Dec.

Potential Drug Interactions in Hospitalized Hematologic Cancer Patients: New Update with New Chemotherapy Regimens

Tahereh Gholipourshahraki  1 , Amir Aria  2 , Mehran Sharifi  3 , Ayda Moghadas  4 , Azadeh Moghaddas  1
Affiliations

Potential Drug Interactions in Hospitalized Hematologic Cancer Patients: New Update with New Chemotherapy Regimens

Tahereh Gholipourshahraki et al. J Res Pharm Pract. .

Abstract

Objective: This cross-sectional study aimed to assess the frequency of potential drug-drug interactions (DDIs) and demographic correlates of moderate and major DDIs among patients with hematologic cancer at a referral hematology hospital in Iran.

Methods: In this study, for 6 months, all patients suffering from hematologic cancers admitted to the tertiary oncology hospital, Omid, Isfahan, were considered. Data from all medications prescribed to patients during hospitalization were analyzed using the online Lexicomp® drug interaction checker, recording all interactions classified by risk level: C, D, or X.

Findings: A total of 674 DDIs were detected in 109 patients. The prevalence of treatments with at least one clinically relevant interaction was 95%, being 57.9% for those at level C and 31.5% for levels D and X. According to the frequency, the main interaction was between aprepitant and corticosteroids, followed by the interaction between aprepitant and vincristine. The most common interaction between antineoplastic agents was between doxorubicin and cyclophosphamide. In terms of mechanism, most of DDIs (54.9%) were pharmacodynamics. Only the number of administered medications was associated with DDI occurrence.

Conclusion: Potential DDIs of moderate to major severity are common among patients with hematologic malignancies. This underscores the importance of implementing different strategies to mitigate this clinically significant risk.

Keywords: Cancer; chemotherapy; drug–drug interactions; hematologic malignancy.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Reliability rating of detected drug–drug interactions (n = 674) according to Lexi-Interact online. DDIs: Drug–drug interactions
See this image and copyright information in PMC

References

    1. Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest. 2006;24:704–12. - PubMed
    1. Muhič N, Mrhar A, Brvar M. Comparative analysis of three drug-drug interaction screening systems against probable clinically relevant drug-drug interactions: A prospective cohort study. Eur J Clin Pharmacol. 2017;73:875–82. - PubMed
    1. Riu-Viladoms G, Carcelero San Martín E, Martín-Conde MT, Creus N. Drug interactions with oral antineoplastic drugs: The role of the pharmacist. Eur J Cancer Care (Engl) 2019;28:e12944. - PubMed
    1. Hadjibabaie M, Badri S, Ataei S, Moslehi AH, Karimzadeh I, Ghavamzadeh A. Potential drug-drug interactions at a referral hematology-oncology ward in Iran: A cross-sectional study. Cancer Chemother Pharmacol. 2013;71:1619–27. - PubMed
    1. Tavousi F, Sadeghi A, Darakhshandeh A, Moghaddas A. Potential drug-drug interactions at a referral pediatric oncology ward in Iran: A cross-sectional study. J Pediatr Hematol Oncol. 2019;41:e146–51. - PubMed

LinkOut - more resources